Creative Biolabs: One-Stop Solutions for Anti-SARS-CoV-2 in the Post-epidemic Era
New York, USA – June 12, 2023 – Despite the fact that the world has entered the post-epidemic era, developing effective vaccines against complex and rapidly evolving SARS-CoV-2 variants remains critical to safeguarding public health. Creative Biolabs provides specialist antiviral services to virus researchers worldwide, working across the full spectrum of coronavirus studies.
Vaccine Development
Creative Biolabs’ vaccine development platform harnesses the power of modified vaccinia virus Ankara strain (MVA) vector technology to develop effective SARS-CoV-2 vaccines. This advanced solution provides a safer and highly immunogenic approach by enabling the presentation of viral antigens on virus-like particles (VLPs).
“The SARS-CoV-2 VLP vaccine with MVA vector demonstrates exceptional potential in inducing robust immune responses against the virus,” said an expert from Creative Biolabs, “besides, our vaccine platform also offers various vaccine development services to meet our customers’ needs.”
For diverse research requirements, Creative Biolabs assists with vaccine services at both preclinical and clinical stages, including but not limited to the following:
* In Silico Vaccine Design for SARS-CoV-2
* SARS-CoV-2 DNA Vaccine
* Recombinant Subunit Vaccine Development
* Analysis & Qualification Service for SARS-CoV-2 Vaccine
Drug Discovery
Recognizing the urgent need for effective antiviral therapeutics, Creative Biolabs is engaged in accelerating anti-SARS-CoV-2 drug discovery, notably through its anti-SARS-CoV-2 peptide discovery service.
Utilizing its extensive peptide library construction and high-throughput screening expertise, Creative Biolabs identifies peptide candidates with high specificity and potency against the virus. By targeting critical viral proteins, these antiviral peptides offer a promising way to disrupt viral replication and inhibit SARS-CoV-2 infection.
Other customized drug discovery services encompass high-throughput screening of new drug candidates, inhibitor discovery, neutralizing antibody development, and broad-spectrum antiviral drug discovery.
Drug Evaluation
“As the efficacy and safety profile of potential drug candidates is paramount to successful research, we provide exceptional support for SARS-CoV-2 drug evaluation,” the expert continued.
Specifically, Creative Biolabs offers the SARS-CoV-2 cytopathic effect detection service to assess the impact of antiviral agents on viral replication and host cell viability. Other assays in the drug evaluation platform accommodate spike-pseudovirus-based neutralization assay, protease inhibitor assay, immunofluorescence-based antiviral assay, etc.
For more information about Creative Biolabs and its anti-SARS-CoV-2 services, please visit https://sars-cov-2.creative-biolabs.com.
About Creative Biolabs
Creative Biolabs is a leading CRO dedicated to delivering innovative solutions in the field of anti-SARS-CoV-2 drug and vaccine development. With cutting-edge technologies, multidisciplinary expertise, and unwavering commitment, Creative Biolabs makes it the preferred choice for global clients seeking diverse solutions to combat this pandemic.
Media Contact
Company Name: Creative Biolabs
Contact Person: Candy Swift
Email: Send Email
Phone: 1-631-830-6441
Country: United States
Website: https://sars-cov-2.creative-biolabs.com
